Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk.
Jennifer L AlejoJake D KimTeresa Po-Yu ChiangRobin K AveryAndrew H KarabaAlexa A JefferisDaniel S WarrenAllan B MassieAaron A R TobianDorry L SegevWilliam A WerbelPublished in: Clinical transplantation (2023)
In this prospective study of patient-reported outcomes, T + C was well tolerated with few serious events. Several COVID-19 breakthroughs were reported, notable as most SOTRs reported changes in risk tolerance after T + C. These results aid counseling of SOTRs regarding real-world safety and effectiveness of T + C.